Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Bristol-Myers Squibb signs $475m option agreement to acquire F-star and FS102 Bristol-Myers Squibb (BMS) has signed an exclusive option agreement for about $475m to acquire F-star Alpha and secure worldwide rights to its lead asset and first clinical compound FS102, a new Phase I ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy. Contract Research & Services > Contract Services > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Medivation, Astellas to initiate Phase III trial of prostate cancer drug enzalutamide
By PBR Staff Writer
Medivation and Astellas are planning to begin a Phase III clinical trial of enzalutamide in men with high-risk, hormone-sensitive, non-metastatic prostate cancer.
News
Auspex begins Phase III AIM-TD trial of SD-809 in patients with tardive dyskinesia
By PBR Staff Writer
Auspex Pharmaceuticals has started patient enrollment in a multi-center Phase III clinical trial of its investigational drug SD-809 (deutetrabenazine) to treat people with tardive dyskinesia, a debilitating and often irreversible movement disorder.
News

Contract Research

Drive AB consortium launched to develop economic models for pharmaceutical industry
By PBR Staff Writer
A new European consortium called Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to combat the rising global threat of antibiotic resistance.
News
Cancer Research UK, Leukaemia & Lymphoma Research partner for new blood cancer drugs
By PBR Staff Writer
Cancer Research UK through its commercial arm has signed an agreement with Leukaemia & Lymphoma Research (LLR) to co-fund the early-phase human clinical trials of experimental blood cancer drugs.
News

Contract Services

Xencor renegotiates XmAb5871 agreement with Amgen
Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, has regained all development and commercial rights to XmAb 5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen.
News
Iroko signs licensing deal with Aspen to market Zorvolex in Australia and New Zealand
By PBR Staff Writer
Iroko Pharmaceuticals has signed a licensing deal with Aspen Pharma to gain exclusive rights to market and sell Zorvolex (diclofenac) capsules in Australia and New Zealand.
News